It owes its drop to lower expenses associated with its Vertex-partnered VX-670 program, which suggests that while past milestones have been lucrative, future revenue contributions from ...

The increase was primarily a result of the approximately $100 million registered direct offering completed in June of 2024 and the receipt of the $75 million payment for the clinical advancement ...